StockNews.com assumed coverage on shares of Organovo (NASDAQ:ONVO – Get Free Report) in a report released on Wednesday. The brokerage set a “sell” rating on the medical research company’s stock.
Organovo Stock Performance
Shares of NASDAQ:ONVO opened at $0.46 on Wednesday. Organovo has a one year low of $0.43 and a one year high of $2.05. The stock has a market capitalization of $6.62 million, a price-to-earnings ratio of -0.29 and a beta of 0.62. The company has a 50-day simple moving average of $0.54 and a 200-day simple moving average of $0.79.
Organovo (NASDAQ:ONVO – Get Free Report) last posted its quarterly earnings data on Monday, August 5th. The medical research company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.15. The company had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.03 million. As a group, research analysts forecast that Organovo will post -0.96 EPS for the current fiscal year.
Institutional Trading of Organovo
Organovo Company Profile
Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.
Further Reading
- Five stocks we like better than Organovo
- Transportation Stocks Investing
- When Is the Best Time to Invest in Mutual Funds?
- Using the MarketBeat Dividend Yield Calculator
- Is NVIDIA Stock in a Correction or Consolidation?
- How to invest in marijuana stocks in 7 stepsĀ
- 3 Oversold Stocks with Big RSI Rebound Potential
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.